Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma | Zendy

Sattva S. Neelapu | Zendy; Frederick L. Locke | Zendy; Nancy L. Bartlett | Zendy; Lazaros J. Lekakis | Zendy; David B. Miklos | Zendy; Caron A. Jacobson | Zendy; Ira Braunschweig | Zendy; Olalekan O. Oluwole | Zendy; Tanya Siddiqi | Zendy; Yi Lin | Zendy; John M. Timmerman | Zendy; Patrick J. Stiff | Zendy; Jonathan W. Friedberg | Zendy; Ian W. Flinn | Zendy; André Goy | Zendy; Brian T. Hill | Zendy; Mitchell R. Smith | Zendy; Abhinav Deol | Zendy; Umar Farooq | Zendy; Peter A. McSweeney | Zendy; Javier Muñoz | Zendy; Irit Avivi | Zendy; Januario E. Castro | Zendy; Jason R. Westin | Zendy; Julio C. Chávez | Zendy; Armin Ghobadi | Zendy; Krishna V. Komanduri | Zendy; Ronald Levy | Zendy; Eric D. Jacobsen | Zendy; Thomas E. Witzig | Zendy; Patrick M. Reagan | Zendy; Adrian Bot | Zendy; John M. Rossi | Zendy; Lynn Navale | Zendy; Yizhou Jiang | Zendy; Jeff Aycock | Zendy; Meg Elias | Zendy; David Chang | Zendy; Jeff Wiezorek | Zendy; William Y. Go | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Author(s) -

Sattva S. Neelapu,

Frederick L. Locke,

Nancy L. Bartlett,

Lazaros J. Lekakis,

David B. Miklos,

Caron A. Jacobson,

Ira Braunschweig,

Olalekan O. Oluwole,

Tanya Siddiqi,

Yi Lin,

John M. Timmerman,

Patrick J. Stiff,

Jonathan W. Friedberg,

Ian W. Flinn,

André Goy,

Brian T. Hill,

Mitchell R. Smith,

Abhinav Deol,

Umar Farooq,

Peter A. McSweeney,

Javier Muñoz,

Irit Avivi,

Januario E. Castro,

Jason R. Westin,

Julio C. Chávez,

Armin Ghobadi,

Krishna V. Komanduri,

Ronald Levy,

Eric D. Jacobsen,

Thomas E. Witzig,

Patrick M. Reagan,

Adrian Bot,

John M. Rossi,

Lynn Navale,

Yizhou Jiang,

Jeff Aycock,

Meg Elias,

David Chang,

Jeff Wiezorek,

William Y. Go

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1707447

Subject(s) - medicine , follicular lymphoma , neutropenia , cytokine release syndrome , fludarabine , gastroenterology , lymphoma , adverse effect , phases of clinical research , regimen , cyclophosphamide , surgery , chimeric antigen receptor , oncology , clinical trial , immunotherapy , chemotherapy , cancer

In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after the failure of conventional therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research